Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Table 2 Patient treatments and outcomes

Duration on Trial (Days)	Starting Dose (mg bd)	Phase II Eligible	Cycles Completed	Mean Compliance (%)	Reason for discontinuing treatment
245	50	No	10	99.6	Patient choice (long journey time)
506	50	No	5	100.0	Toxicity
609	50	No	8	100.0	Completed scheduled 6 treatment cycles
1945	50	No	60	97.6	Progressive disease
68	75	Yes	3	99.7	Progressive disease
90	75	Yes	3	97.6	Toxicity
111	75	Yes	5	100.0	Progressive disease
224	75	Yes	3	81.0	Toxicity
345	75	Yes	6	97.6	Toxicity
379	75	Yes	2	96.4	Toxicity
418	75	Yes	3	73.2	Toxicity
426	75	Yes	4	86.9	Progressive disease
448	75	Yes	5	86.5	Toxicity
477	75	Yes	3	99.2	Progressive disease
498	75	Yes	6	98.0	Completed scheduled 6 treatment cycles
538	75	Yes	6	100.0	Completed scheduled 6 treatment cycles

Note: One patient allocated to 50 mg bd was ineligible, one patient allocated to 75 mg bd was ineligible, and one allocated to 75 mg bd withdrew consent. None received any treatment and are therefore not presented in this table

ISSN: 1471-2407